128 related articles for article (PubMed ID: 30538301)
1. Combination therapy for advanced and metastatic kidney cancer.
Lee CH; Motzer RJ
Nat Rev Urol; 2019 Feb; 16(2):77-78. PubMed ID: 30538301
[No Abstract] [Full Text] [Related]
2. NICE guidance on nivolumab with ipilimumab for untreated advanced renal cell carcinoma.
Adler AI; Brooke A; Elsada A; Landells L
Lancet Oncol; 2019 Jul; 20(7):904-905. PubMed ID: 31103427
[No Abstract] [Full Text] [Related]
3. Improving cancer care in metastatic kidney and prostate cancer: steps in the right direction.
Saad F
Curr Opin Support Palliat Care; 2017 Sep; 11(3):214-215. PubMed ID: 28657926
[No Abstract] [Full Text] [Related]
4. Metastatic renal cell carcinoma: systemic treatment.
Abi-Aad AS; deKernion JB
Acta Urol Belg; 1996 May; 64(2):3-8. PubMed ID: 8701805
[No Abstract] [Full Text] [Related]
5. Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
Gao X; McDermott DF
Cancer J; 2018; 24(4):171-179. PubMed ID: 30119080
[TBL] [Abstract][Full Text] [Related]
6. High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome.
Chow S; Galvis V; Pillai M; Leach R; Keene E; Spencer-Shaw A; Shablak A; Shanks J; Liptrot T; Thistlethwaite F; Hawkins RE
J Immunother Cancer; 2016; 4():67. PubMed ID: 27777776
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab plus ipilimumab in metastatic colorectal cancer.
Gourd E
Lancet Oncol; 2018 Mar; 19(3):e139. PubMed ID: 29395861
[No Abstract] [Full Text] [Related]
8. [Nivolumab combined with ipilimumab versus sunitinib monotherapy-SUNNIFORECAST AN 41/16 of the AUO : A phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma].
Rexer H; Steiner T; Bergmann L
Urologe A; 2017 Jun; 56(6):802-803. PubMed ID: 28536740
[No Abstract] [Full Text] [Related]
9. Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.
Vitale MG; Scagliarini S; Galli L; Pignata S; Lo Re G; Berruti A; Defferrari C; Spada M; Masini C; Santini D; Ciuffreda L; Ruggeri EM; Bengala C; Livi L; Fagnani D; Bonetti A; Giustini L; Hamzaj A; Procopio G; Caserta C; Sabbatini R
PLoS One; 2018; 13(7):e0199642. PubMed ID: 29979712
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib- and bevacizumab-induced reversible heart failure in a patient with metastatic renal cell carcinoma: A case report.
Abdallah AO; Vallurupalli S; Kunthur A
J Oncol Pharm Pract; 2016 Jun; 22(3):561-5. PubMed ID: 25956420
[No Abstract] [Full Text] [Related]
11. [Current aspects in the prognosis of advanced melanoma].
Sirokay-Kohlmeyer J
Hautarzt; 2018 Mar; 69(3):249-259. PubMed ID: 29396638
[TBL] [Abstract][Full Text] [Related]
12. Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.
Martini DJ; Hamieh L; McKay RR; Harshman LC; Brandao R; Norton CK; Steinharter JA; Krajewski KM; Gao X; Schutz FA; McGregor B; Bossé D; Lalani AA; De Velasco G; Michaelson MD; McDermott DF; Choueiri TK
Cancer Immunol Res; 2018 Apr; 6(4):402-408. PubMed ID: 29437040
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
Zarrabi K; Wu S
Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
[TBL] [Abstract][Full Text] [Related]
14. Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review.
Raouf S; Bertelli G; Ograbek A; Field P; Tran I
Future Oncol; 2019 Feb; 15(5):543-561. PubMed ID: 30379088
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for renal cell carcinoma.
Amato RJ
Semin Oncol; 2000 Apr; 27(2):177-86. PubMed ID: 10768596
[TBL] [Abstract][Full Text] [Related]
16. Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?
Di Nunno V; Gatto L; Fragomeno B; Cubelli M; Nobili E; Romano I; Santoni M; Pisconti S; Montironi R; Massari F
Future Oncol; 2018 Dec; 14(29):2997-2999. PubMed ID: 30411632
[No Abstract] [Full Text] [Related]
17. CMV chemotherapy for advanced transitional cell carcinoma.
Jeffery GM; Mead GM
Br J Cancer; 1992 Sep; 66(3):542-6. PubMed ID: 1520591
[TBL] [Abstract][Full Text] [Related]
18. Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.
Umeyama Y; Shibasaki Y; Akaza H
Future Oncol; 2017 Sep; 13(21):1839-1852. PubMed ID: 28707479
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
20. Treatment of recurrent or metastatic renal cell carcinoma.
Shah RN; Ahmad T; Eisen TG
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1069-80. PubMed ID: 15606334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]